Skip to main content
Top
Published in: BMC Infectious Diseases 1/2013

Open Access 01-12-2013 | Research article

Rate of candidiasis among HIV-infected children in Spain in the era of highly active antiretroviral therapy (1997–2008)

Authors: Alejandro Álvaro-Meca, Julia Jensen, Dariela Micheloud, Asunción Díaz, Dolores Gurbindo, Salvador Resino

Published in: BMC Infectious Diseases | Issue 1/2013

Login to get access

Abstract

Background

Candidiasis is the most common opportunistic infection seen in human immunodeficiency virus (HIV)-infected individuals. The aim of our study was to estimate the candidiasis rate and evaluate its trend in HIV-infected children in Spain during the era of highly active antiretroviral therapy (HAART) compared to HIV-uninfected children.

Methods

We carried out a retrospective study. Data were obtained from the records of the Minimum Basic Data Set from hospitals in Spain. All HIV-infected children were under 17 years of age, and a group of HIV-uninfected children with hospital admissions matching the study group by gender and age were randomly selected. The follow-up period (1997–2008) was divided into three calendar periods: a) From 1997 to 1999 for early-period HAART; b) from 2000 to 2002 for mid-period HAART; and c) from 2003 to 2008 for late-period HAART.

Results

Among children with hospital admissions, HIV-infected children had much higher values than HIV-uninfected children during each of the three calendar periods for overall candidiasis rates (150.0 versus 6.1 events per 1,000 child hospital admissions/year (p < 0.001), 90.3 versus 3.1 (p < 0.001), and 79.3 versus 10.7 (p < 0.001), respectively) and for non-invasive Candida mycosis (ICM) rates (118.5 versus 3.8 (p < 0.001), 85.3 versus 2.3 (p < 0.001), and 80.6 versus 6.0 (p < 0.001), respectively). In addition, HIV-infected children also had higher values of ICM rates than HIV-uninfected children, except during the last calendar period when no significant difference was found (32.4 versus 1.2 (p < 0.001), 11.6 versus 0.4 (p < 0.001), and 4.6 versus 2.3 (p = 0.387), respectively). For all children living with HIV/AIDS, the overall candidiasis rate (events per 1,000 HIV-infected children/year) decreased from 1997–1999 to 2000–2002 (18.8 to 10.6; p < 0.001) and from 2000–2002 to 2003–2008 (10.6 to 5.7; p = 0.060). Within each category of candidiasis, both non-ICM and ICM rates experienced significant decreases from 1997–1999 to 2003–2008 (15.9 to 5.7 (p < 0.001) and 4.1 to 0.3 (p < 0.001), respectively).

Conclusions

Although the candidiasis rate still remains higher than in the general population (from 1997 to 2008), candidiasis diagnoses have decreased among HIV-infected children throughout the HAART era, and it has ceased to be a major health problem among children with HIV infection.
Appendix
Available only for authorised users
Literature
1.
go back to reference CDCP: Guidelines for use of antiretroviral agents in pediatric HIV infection. MMWR Morb Mortal Wkly Rep. 1998, 47: 1-43. CDCP: Guidelines for use of antiretroviral agents in pediatric HIV infection. MMWR Morb Mortal Wkly Rep. 1998, 47: 1-43.
2.
go back to reference Mueller BU, Sleasman J, Nelson RP, Smith S, Deutsch PJ, Ju W, Steinberg SM, Balis FM, Jarosinski PF, Brouwers P: A phase I/II study of the protease inhibitor indinavir in children with HIV infection. Pediatrics. 1998, 102 (1): e8-10.1542/peds.102.1.e8.CrossRef Mueller BU, Sleasman J, Nelson RP, Smith S, Deutsch PJ, Ju W, Steinberg SM, Balis FM, Jarosinski PF, Brouwers P: A phase I/II study of the protease inhibitor indinavir in children with HIV infection. Pediatrics. 1998, 102 (1): e8-10.1542/peds.102.1.e8.CrossRef
3.
go back to reference Rutstein RM, Feingold A, Meislich D, Word B, Rudy B: Protease inhibitor therapy in children with perinatally acquired HIV infection. AIDS. 1997, 11: F107-111. 10.1097/00002030-199712000-00004.CrossRefPubMed Rutstein RM, Feingold A, Meislich D, Word B, Rudy B: Protease inhibitor therapy in children with perinatally acquired HIV infection. AIDS. 1997, 11: F107-111. 10.1097/00002030-199712000-00004.CrossRefPubMed
4.
go back to reference Krogstad P, Wiznia A, Luzuriaga K, Dankner W, Nielsen K, Gersten M, Kerr B, Hendricks A, Boczany B, Rosenberg M: Treatment of human immunodeficiency virus 1-infected infants and children with the protease inhibitor nelfinavir mesylate. Clin Infect Dis. 1999, 28 (5): 1109-1118. 10.1086/514759.CrossRefPubMed Krogstad P, Wiznia A, Luzuriaga K, Dankner W, Nielsen K, Gersten M, Kerr B, Hendricks A, Boczany B, Rosenberg M: Treatment of human immunodeficiency virus 1-infected infants and children with the protease inhibitor nelfinavir mesylate. Clin Infect Dis. 1999, 28 (5): 1109-1118. 10.1086/514759.CrossRefPubMed
5.
go back to reference Starr SE, Fletcher CV, Spector SA, Yong FH, Fenton T, Brundage RC, Manion D, Ruiz N, Gersten M, Becker M: Combination therapy with efavirenz, nelfinavir, and nucleoside reverse- transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team. N Engl J Med. 1999, 341 (25): 1874-1881. 10.1056/NEJM199912163412502.CrossRefPubMed Starr SE, Fletcher CV, Spector SA, Yong FH, Fenton T, Brundage RC, Manion D, Ruiz N, Gersten M, Becker M: Combination therapy with efavirenz, nelfinavir, and nucleoside reverse- transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team. N Engl J Med. 1999, 341 (25): 1874-1881. 10.1056/NEJM199912163412502.CrossRefPubMed
6.
go back to reference Resino S, Bellón J, Resino R, Navarro M, Ramos J, Mellado M, de Jose M, Muñoz-Fernández MA: Extensive implementation of highly active antiretroviral therapy shows great effectiveness on the survival and surrogate markers in vertically HIV-infected children. Clin Infect Dis. 2004, 38: 1605-1612. 10.1086/420738.CrossRefPubMed Resino S, Bellón J, Resino R, Navarro M, Ramos J, Mellado M, de Jose M, Muñoz-Fernández MA: Extensive implementation of highly active antiretroviral therapy shows great effectiveness on the survival and surrogate markers in vertically HIV-infected children. Clin Infect Dis. 2004, 38: 1605-1612. 10.1086/420738.CrossRefPubMed
7.
go back to reference Viciana P, Rubio R, Ribera E, Knobel H, Iribarren JA, Arribas JR, Perez-Molina JA: [Longitudinal study on adherence, treatment satisfaction, and effectiveness of once-daily versus twice-daily antiretroviral therapy in a Spanish cohort of HIV-infected patients (CUVA study)]. Enferm Infecc Microbiol Clin. 2008, 26 (3): 127-134. 10.1157/13116748.CrossRefPubMed Viciana P, Rubio R, Ribera E, Knobel H, Iribarren JA, Arribas JR, Perez-Molina JA: [Longitudinal study on adherence, treatment satisfaction, and effectiveness of once-daily versus twice-daily antiretroviral therapy in a Spanish cohort of HIV-infected patients (CUVA study)]. Enferm Infecc Microbiol Clin. 2008, 26 (3): 127-134. 10.1157/13116748.CrossRefPubMed
8.
go back to reference Guillen S, Garcia San Miguel L, Resino S, Bellon JM, Gonzalez I, Jimenez de Ory S, Munoz-Fernandez MA, Navarro ML, Gurbindo MD, De Jose MI: Opportunistic infections and organ-specific diseases in HIV-1-infected children: a cohort study (1990–2006). HIV Med. 2010, 11 (4): 245-252. 10.1111/j.1468-1293.2009.00768.x.CrossRefPubMed Guillen S, Garcia San Miguel L, Resino S, Bellon JM, Gonzalez I, Jimenez de Ory S, Munoz-Fernandez MA, Navarro ML, Gurbindo MD, De Jose MI: Opportunistic infections and organ-specific diseases in HIV-1-infected children: a cohort study (1990–2006). HIV Med. 2010, 11 (4): 245-252. 10.1111/j.1468-1293.2009.00768.x.CrossRefPubMed
9.
go back to reference Brady MT, Oleske JM, Williams PL, Elgie C, Mofenson LM, Dankner WM, Van Dyke RB: Declines in mortality rates and changes in causes of death in HIV-1-infected children during the HAART era. J Acquir Immune Defic Syndr. 2010, 53 (1): 86-94. 10.1097/QAI.0b013e3181b9869f.CrossRefPubMedPubMedCentral Brady MT, Oleske JM, Williams PL, Elgie C, Mofenson LM, Dankner WM, Van Dyke RB: Declines in mortality rates and changes in causes of death in HIV-1-infected children during the HAART era. J Acquir Immune Defic Syndr. 2010, 53 (1): 86-94. 10.1097/QAI.0b013e3181b9869f.CrossRefPubMedPubMedCentral
10.
go back to reference Resino S, Resino R, Micheloud D, Gurbindo Gutierrez D, Leon JA, Ramos JT, Ciria L, de Jose I, Mellado J, Munoz-Fernandez A: Long-term effects of highly active antiretroviral therapy in pretreated, vertically HIV type 1-infected children: 6 years of follow-up. Clin Infect Dis. 2006, 42 (6): 862-869. 10.1086/500412.CrossRefPubMed Resino S, Resino R, Micheloud D, Gurbindo Gutierrez D, Leon JA, Ramos JT, Ciria L, de Jose I, Mellado J, Munoz-Fernandez A: Long-term effects of highly active antiretroviral therapy in pretreated, vertically HIV type 1-infected children: 6 years of follow-up. Clin Infect Dis. 2006, 42 (6): 862-869. 10.1086/500412.CrossRefPubMed
11.
go back to reference Gona P, Van Dyke RB, Williams PL, Dankner WM, Chernoff MC, Nachman SA, Seage GR: Incidence of opportunistic and other infections in HIV-infected children in the HAART era. JAMA. 2006, 296 (3): 292-300. 10.1001/jama.296.3.292.CrossRefPubMed Gona P, Van Dyke RB, Williams PL, Dankner WM, Chernoff MC, Nachman SA, Seage GR: Incidence of opportunistic and other infections in HIV-infected children in the HAART era. JAMA. 2006, 296 (3): 292-300. 10.1001/jama.296.3.292.CrossRefPubMed
12.
go back to reference Resino S, Resino R, Maria Bellon J, Micheloud D, Gutierrez MD, de Jose MI, Ramos JT, Fontelos PM, Ciria L, Munoz-Fernandez MA: Clinical outcomes improve with highly active antiretroviral therapy in vertically HIV type-1-infected children. Clin Infect Dis. 2006, 43 (2): 243-252. 10.1086/505213.CrossRefPubMed Resino S, Resino R, Maria Bellon J, Micheloud D, Gutierrez MD, de Jose MI, Ramos JT, Fontelos PM, Ciria L, Munoz-Fernandez MA: Clinical outcomes improve with highly active antiretroviral therapy in vertically HIV type-1-infected children. Clin Infect Dis. 2006, 43 (2): 243-252. 10.1086/505213.CrossRefPubMed
13.
go back to reference Gibb DM, Duong T, Tookey PA, Sharland M, Tudor-Williams G, Novelli V, Butler K, Riordan A, Farrelly L, Masters J: Decline in mortality, AIDS, and hospital admissions in perinatally HIV-1 infected children in the United Kingdom and Ireland. BMJ. 2003, 327 (7422): 1019-10.1136/bmj.327.7422.1019.CrossRefPubMedPubMedCentral Gibb DM, Duong T, Tookey PA, Sharland M, Tudor-Williams G, Novelli V, Butler K, Riordan A, Farrelly L, Masters J: Decline in mortality, AIDS, and hospital admissions in perinatally HIV-1 infected children in the United Kingdom and Ireland. BMJ. 2003, 327 (7422): 1019-10.1136/bmj.327.7422.1019.CrossRefPubMedPubMedCentral
14.
go back to reference Kourtis AP, Bansil P, Posner SF, Johnson C, Jamieson DJ: Trends in hospitalizations of HIV-infected children and adolescents in the United States: analysis of data from the 1994–2003 Nationwide Inpatient Sample. Pediatrics. 2007, 120 (2): e236-243. 10.1542/peds.2006-3268.CrossRefPubMed Kourtis AP, Bansil P, Posner SF, Johnson C, Jamieson DJ: Trends in hospitalizations of HIV-infected children and adolescents in the United States: analysis of data from the 1994–2003 Nationwide Inpatient Sample. Pediatrics. 2007, 120 (2): e236-243. 10.1542/peds.2006-3268.CrossRefPubMed
15.
go back to reference de Martino M, Tovo PA, Balducci M, Galli L, Gabiano C, Rezza G, Pezzotti P: Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. Italian register for HIV infection in children and the italian national AIDS registry. JAMA. 2000, 284 (2): 190-197. 10.1001/jama.284.2.190.CrossRefPubMed de Martino M, Tovo PA, Balducci M, Galli L, Gabiano C, Rezza G, Pezzotti P: Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. Italian register for HIV infection in children and the italian national AIDS registry. JAMA. 2000, 284 (2): 190-197. 10.1001/jama.284.2.190.CrossRefPubMed
16.
go back to reference Mofenson LM, Brady MT, Danner SP, Dominguez KL, Hazra R, Handelsman E, Havens P, Nesheim S, Read JS, Serchuck L: Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children: recommendations from CDC, the national institutes of health, the HIV medicine association of the infectious diseases society of america, the pediatric infectious diseases society, and the american academy of pediatrics. MMWR Recommendations and reports: Morbidity and mortality weekly report Recommendations and reports / Centers for Disease Control. 2009, 58 (RR-11): 1-166. Mofenson LM, Brady MT, Danner SP, Dominguez KL, Hazra R, Handelsman E, Havens P, Nesheim S, Read JS, Serchuck L: Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children: recommendations from CDC, the national institutes of health, the HIV medicine association of the infectious diseases society of america, the pediatric infectious diseases society, and the american academy of pediatrics. MMWR Recommendations and reports: Morbidity and mortality weekly report Recommendations and reports / Centers for Disease Control. 2009, 58 (RR-11): 1-166.
17.
go back to reference Pfaller MA, Diekema DJ: Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev. 2007, 20 (1): 133-163. 10.1128/CMR.00029-06.CrossRefPubMedPubMedCentral Pfaller MA, Diekema DJ: Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev. 2007, 20 (1): 133-163. 10.1128/CMR.00029-06.CrossRefPubMedPubMedCentral
18.
go back to reference Nesheim SR, Kapogiannis BG, Soe MM, Sullivan KM, Abrams E, Farley J, Palumbo P, Koenig LJ, Bulterys M: Trends in opportunistic infections in the pre- and post-highly active antiretroviral therapy eras among HIV-infected children in the Perinatal AIDS Collaborative Transmission Study, 1986–2004. Pediatrics. 2007, 120 (1): 100-109. 10.1542/peds.2006-2052.CrossRefPubMed Nesheim SR, Kapogiannis BG, Soe MM, Sullivan KM, Abrams E, Farley J, Palumbo P, Koenig LJ, Bulterys M: Trends in opportunistic infections in the pre- and post-highly active antiretroviral therapy eras among HIV-infected children in the Perinatal AIDS Collaborative Transmission Study, 1986–2004. Pediatrics. 2007, 120 (1): 100-109. 10.1542/peds.2006-2052.CrossRefPubMed
19.
go back to reference Weinberg A, Dickover R, Britto P, Hu C, Patterson-Bartlett J, Kraimer J, Gutzman H, Shearer WT, Rathore M, McKinney R: Continuous improvement in the immune system of HIV-infected children on prolonged antiretroviral therapy. AIDS. 2008, 22 (17): 2267-2277. 10.1097/QAD.0b013e3283189bb3.CrossRefPubMedPubMedCentral Weinberg A, Dickover R, Britto P, Hu C, Patterson-Bartlett J, Kraimer J, Gutzman H, Shearer WT, Rathore M, McKinney R: Continuous improvement in the immune system of HIV-infected children on prolonged antiretroviral therapy. AIDS. 2008, 22 (17): 2267-2277. 10.1097/QAD.0b013e3283189bb3.CrossRefPubMedPubMedCentral
20.
go back to reference Weinberg A, Pahwa S, Oyomopito R, Carey VJ, Zimmer B, Mofenson L, Kovacs A, Burchett SK: Antimicrobial-specific cell-mediated immune reconstitution in children with advanced human immunodeficiency virus infection receiving highly active antiretroviral therapy. Clin Infect Dis. 2004, 39 (1): 107-114. 10.1086/420931.CrossRefPubMed Weinberg A, Pahwa S, Oyomopito R, Carey VJ, Zimmer B, Mofenson L, Kovacs A, Burchett SK: Antimicrobial-specific cell-mediated immune reconstitution in children with advanced human immunodeficiency virus infection receiving highly active antiretroviral therapy. Clin Infect Dis. 2004, 39 (1): 107-114. 10.1086/420931.CrossRefPubMed
21.
go back to reference Alvaro-Meca A, Micheloud D, Jensen J, Diaz A, Garcia-Alvarez M, Resino S: Epidemiologic trends of cancer diagnoses among HIV-infected children in Spain from 1997 to 2008. Pediatr Infect Dis J. 2011, 30 (9): 764-768. 10.1097/INF.0b013e31821ba148.CrossRefPubMed Alvaro-Meca A, Micheloud D, Jensen J, Diaz A, Garcia-Alvarez M, Resino S: Epidemiologic trends of cancer diagnoses among HIV-infected children in Spain from 1997 to 2008. Pediatr Infect Dis J. 2011, 30 (9): 764-768. 10.1097/INF.0b013e31821ba148.CrossRefPubMed
22.
go back to reference Chiappini E, Galli L, Tovo PA, Gabiano C, Lisi C, Gattinara GC, Esposito S, Vigano A, Giaquinto C, Rosso R: Changing patterns of clinical events in perinatally HIV-1-infected children during the era of HAART. AIDS. 2007, 21 (12): 1607-1615. 10.1097/QAD.0b013e32823ecf5b.CrossRefPubMed Chiappini E, Galli L, Tovo PA, Gabiano C, Lisi C, Gattinara GC, Esposito S, Vigano A, Giaquinto C, Rosso R: Changing patterns of clinical events in perinatally HIV-1-infected children during the era of HAART. AIDS. 2007, 21 (12): 1607-1615. 10.1097/QAD.0b013e32823ecf5b.CrossRefPubMed
23.
go back to reference Sharland M, Blanche S, Castelli G, Ramos J, Gibb DM: PENTA guidelines for the use of antiretroviral therapy, 2004. HIV Med. 2004, 5 (Suppl 2): 61-86.CrossRefPubMed Sharland M, Blanche S, Castelli G, Ramos J, Gibb DM: PENTA guidelines for the use of antiretroviral therapy, 2004. HIV Med. 2004, 5 (Suppl 2): 61-86.CrossRefPubMed
24.
go back to reference Hacimustafaoglu M, Celebi S: Candida infections in non-neutropenic children after the neonatal period. Expert Rev Anti Infect Ther. 2011, 9 (10): 923-940. 10.1586/eri.11.104.CrossRefPubMed Hacimustafaoglu M, Celebi S: Candida infections in non-neutropenic children after the neonatal period. Expert Rev Anti Infect Ther. 2011, 9 (10): 923-940. 10.1586/eri.11.104.CrossRefPubMed
25.
go back to reference Kao AS, Brandt ME, Pruitt WR, Conn LA, Perkins BA, Stephens DS, Baughman WS, Reingold AL, Rothrock GA, Pfaller MA: The epidemiology of candidemia in two United States cities: results of a population-based active surveillance. Clin Infect Dis. 1999, 29 (5): 1164-1170. 10.1086/313450.CrossRefPubMed Kao AS, Brandt ME, Pruitt WR, Conn LA, Perkins BA, Stephens DS, Baughman WS, Reingold AL, Rothrock GA, Pfaller MA: The epidemiology of candidemia in two United States cities: results of a population-based active surveillance. Clin Infect Dis. 1999, 29 (5): 1164-1170. 10.1086/313450.CrossRefPubMed
26.
go back to reference Neu N, Malik M, Lunding A, Whittier S, Alba L, Kubin C, Saiman L: Epidemiology of candidemia at a Children’s hospital, 2002 to 2006. Pediatr Infect Dis J. 2009, 28 (9): 806-809. 10.1097/INF.0b013e3181a0d78d.CrossRefPubMed Neu N, Malik M, Lunding A, Whittier S, Alba L, Kubin C, Saiman L: Epidemiology of candidemia at a Children’s hospital, 2002 to 2006. Pediatr Infect Dis J. 2009, 28 (9): 806-809. 10.1097/INF.0b013e3181a0d78d.CrossRefPubMed
Metadata
Title
Rate of candidiasis among HIV-infected children in Spain in the era of highly active antiretroviral therapy (1997–2008)
Authors
Alejandro Álvaro-Meca
Julia Jensen
Dariela Micheloud
Asunción Díaz
Dolores Gurbindo
Salvador Resino
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2013
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/1471-2334-13-115

Other articles of this Issue 1/2013

BMC Infectious Diseases 1/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine